Champlain Investment Partners LLC Has $203.30 Million Position in Edwards Lifesciences Co. (NYSE:EW)

Champlain Investment Partners LLC grew its position in Edwards Lifesciences Co. (NYSE:EW) by 4.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,080,703 shares of the medical research company’s stock after purchasing an additional 132,515 shares during the period. Edwards Lifesciences comprises approximately 1.2% of Champlain Investment Partners LLC’s holdings, making the stock its 29th biggest holding. Champlain Investment Partners LLC owned about 0.52% of Edwards Lifesciences worth $203,296,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Cetera Advisors LLC increased its holdings in Edwards Lifesciences by 175.1% during the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after purchasing an additional 24,242 shares in the last quarter. BDF Gestion acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at $5,148,000. Tidal Investments LLC raised its holdings in shares of Edwards Lifesciences by 54.7% in the first quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock valued at $2,890,000 after buying an additional 10,700 shares during the last quarter. Raymond James & Associates lifted its position in Edwards Lifesciences by 2.8% during the 2nd quarter. Raymond James & Associates now owns 1,825,230 shares of the medical research company’s stock worth $168,597,000 after buying an additional 50,124 shares in the last quarter. Finally, AIA Group Ltd grew its holdings in Edwards Lifesciences by 91.7% during the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after acquiring an additional 358,556 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,000 shares of company stock valued at $2,657,000. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Up 0.2 %

NYSE EW opened at $70.49 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market cap of $41.58 billion, a P/E ratio of 10.17, a P/E/G ratio of 3.96 and a beta of 1.12. The stock’s 50-day moving average is $67.70 and its 200-day moving average is $75.73.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the company posted $0.59 EPS. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EW. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 11th. Jefferies Financial Group lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the company from $85.00 to $70.00 in a research report on Wednesday, September 18th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Robert W. Baird decreased their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.